Improving drug development for rare cancers using a new testing method
Official title: Reimagining Pharmaceutical Drug Development in Oncology with a Biomimetic Platform
Funded at Teo Therapeutics Incorporated · NIH-10920344 · Data updated 2026-11-12
This study is working on a faster and cheaper way to develop new drugs for rare cancers that don’t have good treatments yet, using a special lab method that helps find promising options more quickly without needing a lot of animal testing.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Teo Therapeutics Incorporated NIH-funded |
| Lab location | 1 site (Beaverton, United States) |
| Project start | September 1, 2024 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $270,428 |
| NIH project number | 1R43OD037620-01 |
| Project ID | NIH-10920344 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with rare cancers who have limited treatment options available.
✕Less likely to help
Patients with common cancers or those who do not have a diagnosis of cancer may not benefit from this research.
What this research studies
This research focuses on creating a more efficient process for developing drugs specifically for rare cancers that currently lack effective treatments. By utilizing a novel biomimetic platform, the researchers aim to streamline the early stages of drug development, allowing for quicker identification of promising drug candidates. The approach involves using a unique quail xenograft assay that can be performed in standard labs, reducing the need for extensive animal testing and associated costs. This innovative method could significantly shorten the timeline and expenses involved in bringing new cancer therapies to patients.
Why it matters
Potential benefit: If successful, this research could lead to faster and more cost-effective development of new therapies for rare cancers, ultimately improving patient outcomes.
How similar studies have gone: Other research has shown promise in using innovative testing methods to accelerate drug development, suggesting that this approach could also be successful.
Where this research is happening
-
Teo Therapeutics Incorporated
Beaverton, United States Active
Researchers
- Principal investigator: Keller, Charles — Teo Therapeutics Incorporated
- Study coordinator: Keller, Charles
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.